Moderna, Inc. $MRNA Shares Acquired by AXQ Capital LP

AXQ Capital LP increased its stake in Moderna, Inc. (NASDAQ:MRNA) by 115.4% during the 3rd quarter, Holdings Channel reports. The fund owned 21,749 shares of the company’s stock after purchasing an additional 11,650 shares during the quarter. AXQ Capital LP’s holdings in Moderna were worth $562,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Parkside Financial Bank & Trust increased its holdings in Moderna by 19.0% during the 2nd quarter. Parkside Financial Bank & Trust now owns 2,347 shares of the company’s stock worth $65,000 after purchasing an additional 375 shares during the period. Amalgamated Bank boosted its stake in shares of Moderna by 0.6% in the 2nd quarter. Amalgamated Bank now owns 65,458 shares of the company’s stock valued at $1,806,000 after buying an additional 408 shares during the period. Rothschild Investment LLC grew its position in shares of Moderna by 94.1% during the second quarter. Rothschild Investment LLC now owns 920 shares of the company’s stock worth $25,000 after buying an additional 446 shares in the last quarter. State of Michigan Retirement System increased its stake in shares of Moderna by 0.8% during the second quarter. State of Michigan Retirement System now owns 92,541 shares of the company’s stock worth $2,553,000 after buying an additional 700 shares during the period. Finally, Cibc World Market Inc. raised its holdings in Moderna by 2.8% in the third quarter. Cibc World Market Inc. now owns 25,832 shares of the company’s stock valued at $667,000 after acquiring an additional 700 shares in the last quarter. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Moderna

In other news, Director Noubar Afeyan sold 23,853 shares of the stock in a transaction dated Thursday, December 11th. The shares were sold at an average price of $29.48, for a total transaction of $703,186.44. Following the completion of the sale, the director owned 3,924 shares in the company, valued at approximately $115,679.52. This represents a 85.87% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 10.90% of the company’s stock.

Moderna Stock Performance

Shares of MRNA opened at $50.52 on Wednesday. The company’s 50 day simple moving average is $39.84 and its 200-day simple moving average is $30.83. The firm has a market cap of $19.95 billion, a PE ratio of -6.95 and a beta of 1.32. Moderna, Inc. has a 12-month low of $22.28 and a 12-month high of $55.20. The company has a current ratio of 3.29, a quick ratio of 3.22 and a debt-to-equity ratio of 0.07.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings results on Friday, February 13th. The company reported ($2.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.79) by $0.68. Moderna had a negative net margin of 145.16% and a negative return on equity of 30.15%. The firm had revenue of $678.00 million during the quarter, compared to analysts’ expectations of $611.14 million. During the same quarter in the prior year, the business earned ($2.91) EPS. Moderna’s quarterly revenue was down 33.2% compared to the same quarter last year. As a group, equities analysts predict that Moderna, Inc. will post -9.61 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have commented on MRNA. Bank of America dropped their price objective on shares of Moderna from $24.00 to $21.00 and set an “underperform” rating on the stock in a research report on Monday, November 10th. The Goldman Sachs Group boosted their target price on shares of Moderna from $36.00 to $41.00 and gave the stock a “neutral” rating in a research note on Tuesday, February 17th. Evercore set a $35.00 price target on Moderna in a research note on Tuesday, February 17th. UBS Group reaffirmed a “neutral” rating and set a $36.00 price target on shares of Moderna in a report on Monday, February 16th. Finally, Citigroup reiterated a “neutral” rating on shares of Moderna in a report on Monday, February 16th. Two investment analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and five have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Reduce” and an average price target of $31.87.

Moderna Company Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.